Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development

Clinical Oncology

Volumn 12, Issue 1, 2000, Pages 2-15

  Harrington, K J ^a,b   Lewanski, C R ^a,c   Stewart, J S W ^c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b MAYO CLINIC   (United States)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; LIPOSOME; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TARGETING; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0034060056     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9104     Document Type: Review

References (64)

1. Lasic D D, Papahadjopoulos D. Liposomes revisited. Science. 267:1995;1275-1276.
2. Ranson M, Howell A, Cheeseman S. Liposomal drug delivery. Cancer Treat Rev. 22:1996;365-379.
3. Bangham A D, Standish H M, Watkins J C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13:1965;238-252.
4. Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res. 9:1968;310-318.
5. Bangham A D. Membrane models with phospholipids. Prog Biophys Mol Biol. 18:1968;29-95.
6. Gregoriades G, Swain C P, Wills E J. Drug -carrier potential of liposomes in cancer chemotherapy. Lancet. i:1974;1313-1316.
7. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med. 295:1976;704-710.
8. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med. 295:1976;765-770.
9. Perez-Soler R. Liposomes as carriers of antitumour agents: toward a clinical reality. Cancer Treat Rev. 16:1989;67-82.
10. Leyland-Jones B. Targeted drug delivery. Semin Oncol. 20:1993;12-17.
11. Martin F J. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology. 11:1997;11-20.
12. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14:1994;S3-S7.
13. Ng T T, Denning D W. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom Compassionate use data. Arch Intern Med. 155:1995;1093-1098.
14. Russo R, Nigro L C, Minniti S. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect. 32:1996;133-137.
15. Prentice H G, Hann I M, Herbrecht R. A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 98:1997;711-718.
16. Durocher J R, Payne R C, Conrad M E. Role of sialic acid in erythrocyte survival. Blood. 45:1975;11-20.
17. Allen T M, Chonn A. Large unilamellar liposomes with low uptake by the reticuloendothelial system. FEBS Lett. 223:1987;42-46.
18. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours. Proc Natl Acad Sci U S A. 85:1988;6949-6953.
19. Klibanov A L, Maruyama K, Torchilin V P. Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes. FEBS Lett. 268:1990;235-237.
20. Papahadjopoulos D, Allen T M, Gabizon A. Sterically stabilised liposomes: Improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc Natl Acad Sci U S A. 88:1991;11460-11464.
21. Lasic D D. Doxorubicin in sterically stabilised liposomes. Nature. 380:1996;561-562.
22. Gabizon A A. Liposomal anthracyclines. Hematol Oncol Clin North Am. 8:1994;431-450.
23. Gabizon A, Dagan A, Goren D. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumour activity in mice. Cancer Res. 42:1982;4734-4739.
24. Gabizon A, Goren D, Fuks Z. Enhancement of adriamycin delivery to liver metastatic cells with increased tumouricidal effect using liposomes as drug carriers. Cancer Res. 43:1983;4730-4735.
25. Proffitt R T, Williams L E, Presant C A. Tumour-imaging potential of liposomes loaded with In -111-NTA: biodistribution in mice. J Nucl Med. 24:1983;45-51.
26. Forssen E A, Coulter D M, Proffitt R T. Selective in vivo localisation of daunorubicin small unilamellar vesicles in solid tumours. Cancer Res. 52:1992;3255-3261.
27. Forssen E A, Male-Brune R, Adler-Moore J P. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56:1996;2066-2075.
28. Harasym T O, Cullis P R, Bally M B. Intratumour distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol. 40:1997;309-317.
29. Ogihara-Umeda I, Sasaki T, Kojima S. Optimal radiolabeled liposomes for tumor imaging. J Nucl Med. 37:1996;326-332.
30. Khokhar A R, Wright K, Siddik Z H. Organ distribution and tumour uptake of liposome entrapped cis -bis-neodecanoato-trans-R,R -1, 2-diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol. 22:1988;223-227.
31. Vadiei K, Siddik Z H, Khokhar A R. Pharmacokinetics of liposome-entrapped cis -bis-neodecanoato trans-R,R-1,2 -diaminocyclohexane platinum (II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol. 30:1992;365-369.
32. Gabizon A, Shiota R, Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst. 81:1989;1484-1488.
33. Gabizon A, Price D C, Huberty J. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50:1990;6371-6378.
34. Gabizon A A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:1992;891-896.
35. Huang S K, Mayhew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilised liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52:1992;6774-6781.
36. Huang S K, Lee K -D, Hong K. Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
37. Huang S K, Martin F J, Jay G. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol. 143:1993;1-14.
38. Vaage J, Barbera-Guillem E, Abra R. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer. 73:1994;1478-1484.
39. Vaage J, Donovan D, Uster P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer. 75:1997;482-486.
40. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilised liposomes for the treatment of a brain tumour model: biodistribution and therapeutic efficacy. J Neurosurg. 83:1995;1029-1037.
41. Newman M S, Colbern G T, Working P K. Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long -circulating, pegylated liposomes (SPI-077) in tumour-bearing mice. Cancer Chemother Pharmacol. 43:1999;1-7.
42. Rahman A, Kessler A, More N. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 40:1980;1532-1537.
43. van Hoesel QG CM, Steerenberg P A, Crommelin D JA. Reduced cardiotoxicity and nephrotoxicity with preservation of anti-tumor activity of doxorubicin entrapped in stable liposomes in the LIEU/M Wsl rat. Cancer Res. 44:1984;3698-3703.
44. Gabizon A, Goren D, Fuks Z. Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model. Br J Cancer. 51:1985;681-689.
45. Forssen E A, Tokes Z A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res. 43:1983;546-550.
46. Mayhew E G, Goldrosen M H, Vaage J. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst. 78:1987;707-713.
47. Gabizon A, Meshorer A, Barenholz Y. Comparative longterm study of the toxicities of free and liposomeassociated doxorubicin in mice after intravenous administration. J Natl Cancer Inst. 77:1986;459-469.
48. Forssen E A, Ross M E. DaunoXome* treatment of solid tumours; preclinical and clinical investigations. J Liposome Res. 4:1994;481-512.
49. Steerenberg P A, Storm G, de Groot G. Liposomes as drug carrier system for cis -diamminedichloroplatinum (II). II: Antitumour activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. Cancer Chemother Pharmacol. 21:1988;299-307.
50. Gondal J A, Preuss H G, Swartz R. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur J Cancer. 29A:1993;1536-1542.
51. Perez-Soler R, Khokhar A R, Lopez -Berenstein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis -bis-neodecanoato trans-R,R -1, 2-diaminocyclohexane platinum (II) entrapped in multilamellar vesicles. Cancer Res. 47:1987;6462-6466.
52. Perez-Soler R, Young L Y, Drewinko B. Increased cytotoxicity and reversal of resistance to cisplatin with entrapment of cis-bis-neodecanoato trans-R,R-1,2-diaminocyclohexane platinum (II) in multilamellar vesicles. Cancer Res. 48:1988;4509-4512.
53. Khokhar A R, al-Baker S, Krakoff I H. Toxicity and antitumour activity of cis-bis -carboxylato(trans-R,R-1,2 -diaminocyclohexane)platinum (II) complexes entrapped in liposomes. Cancer Chemother Pharmacol. 23:1989;219-224.
54. Working P K, Newman M S, Huang S K. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J Liposome Res. 4:1994;667-687.
55. Mayhew E G, Lasic D, Babbar S. Pharmacokinetics and antitumour activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer. 51:1992;302-309.
56. Vaage J, Mayhew E, Lasic D. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer. 51:1992;942-948.
57. Vaage J, Donovan D, Loftus T. Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br J Cancer. 72:1995;1074-1075.
58. Vaage J, Donovan D, Mayhew E. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilised liposomes. Cancer. 72:1993;3671-3675.
59. Williams S S, Alosco T R, Mayhew E. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilised liposomes. Cancer Res. 53:1993;3964-3967.
60. Vaage J, Donovan D, Mayhew E. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilised liposomes. Int J Cancer. 54:1993;959-964.
61. Chang C W, Barber L, Ouyang C. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilised liposomes after intravenous administration in BDF1 mice. Br J Cancer. 75:1997;169-177.
62. Mori A, Wu S -P, Han I. In vivo antitumour activity of cis-bis -neodecanoato-trans-R,R-1,2 -diaminocyclohexane platinum(II) formulated in long -circulating liposomes. Cancer Chemother Pharmacol. 37:1996;435-444.
63. Vaage J, Donovan D, Wipff E. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer. 80:1999;134-137.
64. Harrington K J, Lewanski C R, Stewart J SW. Liposomes as vehicles for targeted therapy of cancer; Part 2: Clinical development. Clin Oncol. 12:2000;16-24.